Even though there are currently five approved CAR-T products in the market, the industry is still in the early phase of development and a number of key challenges for industrializing CGT therapies have not yet been addressed. One of these challenges is to manage and scale supply chains and manufacturing operations across the globe for an individualized treatment.
During the BINOCS User Meeting in October 2021, we hosted a panel of experts in the field to highlight the current challenges in scaling up interconnected supply chain and manufacturing operations for CGT products.
In this whitepaper, you will learn from our panel of experts:
We’ll keep your email address safe.
We do not share your details with third parties.